Predicting HIV RNA Virologic Outcome at 52-Weeks Follow-Up in Antiretroviral Clinical Trials
- 1 August 2000
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 24 (5) , 433-439
- https://doi.org/10.1097/00042560-200008150-00006
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patientsAIDS, 2000
- 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1998
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- British HIV Association guidelines for antiretroviral treatment of HIV seropositive individualsThe Lancet, 1997
- The meaning and use of the area under a receiver operating characteristic (ROC) curve.Radiology, 1982